Cancel
See Linkedin
Known information
- Worked at Medivation
- Worked at InterMune
- Oversaw InterMune’s global IP portfolio
- Supported the approval and commercialization of Esbriet®
- Helped establish and administer InterMune’s European subsidiaries
- Assisted in public offerings and common stock before InterMune’s acquisition by Roche
- Has expertise in transactions, intellectual property, securities, and corporate governance in the U.S. and Europe
About Arcus Biosciences
Arcus Biosciences develops differentiated molecules and combination therapies for cancer treatment, with a clinical pipeline that includes domvanalimab, etrumadenant, and zimberelimab. The company partners with Gilead Sciences and Taiho Pharmaceutical and conducts global clinical trials in various cancer types.
Report inaccurate information